Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Zealand Pharma AS (ZEAL) DKK1

Sell:225.60 DKK Buy:226.00 DKK Change: 11.60 DKK (5.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:225.60 DKK
Buy:226.00 DKK
Change: 11.60 DKK (5.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:225.60 DKK
Buy:226.00 DKK
Change: 11.60 DKK (5.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

Contact details

Address:
Smedeland 36
GLOSTRUP
2600
Denmark
Telephone:
+45 () 88773600
Website:
https://www.zealandpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZEAL
ISIN:
DK0060257814
Market cap:
7.69 billion DKK
Shares in issue:
35.80 million
Sector:
Biotechnology
Exchange:
Copenhagen Stock Exchange
Country:
Denmark
Currency:
Danish Krone
Indices:
n/a

Key personnel

  • Alf Nicklasson
    Independent Chairman of the Board
  • Emmanuel Dulac
    Chief Executive Officer
  • Kirsten Drejer
    Independent Vice Chairman of the Board
  • Matthew Dallas
    Chief Financial Officer, Senior Vice President
  • Adam Steensberg
    Executive Vice President, Chief Medical and Development Officer (CMDO)
  • Marino Garcia
    Senior Vice President, Corporate and Business Development
  • Ivan Moeller
    President of Technical Development & Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.